核输出蛋白XPO1是ZFTA-RELA室管膜瘤的治疗弱点
该研究针对缺乏靶向治疗的儿童室管膜瘤,特别是ZFTA-RELA融合驱动的幕上室管膜瘤,通过CRISPR-Cas9全基因组筛选发现XPO1等ZR相互作用蛋白。XPO1抑制剂selinexor可损害ZR驱动的小鼠模型肿瘤生长并延长生存,与吉西他滨和ribociclib联用进一步延长生存,提示该联合方案可快速转化为临床试验。
要点
- XPO1抑制剂selinexor可穿过血脑屏障,已获FDA批准并有儿童安全性数据。
- ZR核内水平需维持「金发姑娘」平衡,过高反而使肿瘤细胞退出细胞周期。
- selinexor联合吉西他滨和ribociclib可进一步延长ZR驱动小鼠模型的生存。
核心结论
- ZR相互作用蛋白构成治疗靶点,XPO1对调节ZR核表达水平至关重要。
- selinexor联合吉西他滨和ribociclib的新型联合治疗可能立即转化为ZFTA-RELA室管膜瘤的临床试验。
研究设计与样本
- 采用CRISPR-Cas9混合筛选鉴定ZR相互作用蛋白,并在ZR驱动的患者来源小鼠模型中进行体内验证。
主要发现
- 筛选鉴定出XPO1、CARM1、SMARCA4和CDK1等可成药的ZR相互作用蛋白。
- ZR核内水平受XPO1调节,且特定核内ZR水平是细胞增殖所必需。
- 与缺陷型ZR DNA结合突变体相比,核内ZR蓄积增加不增强致癌基因表达,反而驱动肿瘤细胞退出细胞周期。
- selinexor治疗ZR驱动患者来源小鼠模型可损害细胞生长并延长动物体内生存。
- selinexor联合吉西他滨和ribociclib进一步延长小鼠生存。
关键数值与推荐
- 大多数XPO1抑制剂(如selinexor)可穿过血脑屏障,已获FDA批准,并有儿童安全性记录。
- selinexor联合吉西他滨和ribociclib的方案已在St. Jude儿童研究医院针对复发室管膜瘤的临床试验(SJDAWN)中使用。
临床怎么用
- 对于ZFTA-RELA室管膜瘤患者,XPO1抑制剂selinexor联合吉西他滨和ribociclib可能成为可快速转化的靶向治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ependymoma (EPN) is the third most common pediatric brain tumor with no targeted therapies available to patients. In supratentorial ependymoma, the most frequent driver alteration is a gene fusion between ZFTA and RELA (denoted ZR), which leads to constitutive localization of ZR in the nucleus. Because ZR is not currently druggable, we tested whether ZR expression leads to aberrant protein interactions that could represent therapeutic vulnerabilities. METHODS: Using CRISPR-Cas9 pooled screening, we identified many novel druggable ZR-interacting proteins including XPO1, CARM1, SMARCA4, and CDK1. We focused on the nuclear export protein (XPO1), given the ability of most XPO1 inhibitors (ie, selinexor) to cross the blood-brain barrier, FDA approval, and have documented safety profiles in children. RESULTS: We found that specific nuclear ZR levels are needed for cell proliferation and are regulated by XPO1. Increased ZR accumulation in the nucleus does not increase oncogenic gene expression but drives tumor cells out of the cell cycle, as compared to a defective ZR DNA-binding mutant. Treatment of ZR-driven patient-derived mouse models with selinexor impairs cell growth and extends survival of animals in vivo. The combination of selinexor treatment with gemcitabine and ribociclib (used in a clinical trial for relapsed EPN at St. Jude Children's Research Hospital [SJDAWN]) further extends mouse survival. CONCLUSION: Our findings demonstrate that ZR-interacting proteins constitute therapeutic leads and that XPO1 is critical for titrating "goldilocks" levels of ZR nuclear expression. We identify a novel combination therapy of selinexor, gemcitabine, and ribociclib that may be immediately translated into clinical trials for EPN patients that are currently without targeted treatments.
引用
- Ippagunta SM, Arabzade A, Varadharajan S, et al. Nuclear export as a therapeutic vulnerability in ZFTA-RELA ependymoma. Neuro Oncol. 2026. PMID: 42080900. doi:10.1093/neuonc/noag100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。